{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-256958","form_type":"8-K","ticker":"TECX","cik":"0001681087","company_name":"Tectonic Therapeutic, Inc.","filed_at":"2025-10-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.133502+00:00","generated_at":"2026-05-17T01:22:10.609737+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Tectonic Therapeutic reports positive Phase 1b Part B data for TX45 in PH-HFrEF","bullets":["Single dose of TX45 improved left heart function and pulmonary hemodynamics: PCWP -29.2%, CO +17.3%, mPAP -19.3%, TPR -29.2% mean change.","In CpcPH patients (PVR>3 WU), PVR reduced -19.7%; PVR >2 WU group showed -10.3% mean change.","Echocardiographic improvements at day 29: LVEF +19.4%, RVFAC +20.3%, TAPSE/SPAP +36.3% mean change.","TX45 well tolerated with no serious or severe adverse events, no clinically significant BP changes or immune reactions.","APEX Phase 2 trial in PH-HFpEF ongoing; topline results expected in 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-256958","json":"https://secwatch.observer/filing/0001193125-25-256958.json","markdown":"https://secwatch.observer/filing/0001193125-25-256958.md","text":"https://secwatch.observer/filing/0001193125-25-256958.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1681087/000119312525256958/0001193125-25-256958-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1681087/000119312525256958/d30823d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T01:22:10.609737+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}